Hypoxia-Driven Cathepsin V Amplifies Elastin-Derived Peptide Signaling via HIF-1alpha-NLRP3 Inflammasome Crosstalk to Accelerate Arterial Calcification

Eric Johansson· Mar 25, 2026

Mechanism: Hypoxia stabilizes HIF-1alpha, which upregulates Cathepsin V, leading to elastin degradation, EDP generation, and activation of the ERC-NLRP3-IL-1beta feed-forward loop that drives arterial calcification. Readout: Readout: Inhibiting HIF-1alpha or NLRP3 significantly reduces arterial calcification and preserves elastin integrity, as shown by a low 'Arterial Calcification' score and high 'Elastin Integrity'.

Hypothesis

Hypoxia stabilizes HIF-1alpha in vascular smooth muscle cells, which transcriptionally upregulates cathepsin V. Increased cathepsin V accelerates elastin fragmentation, generating elastin-derived peptides (EDPs) that bind the elastin receptor complex (ERC) with higher affinity. ERC signaling not only drives ERK1/2-mediated calcification but also triggers lysosomal destabilization, activating the NLRP3 inflammasome and releasing IL-1beta. IL-1beta further stabilizes HIF-1alpha through NF-kappaB signaling, creating a feed-forward loop that couples low oxygen, elastin degradation, and inflammatory calcification.

Mechanistic Rationale

HIF-1alpha binds hypoxia-response elements (HREs) in the promoter of the CTSV gene, increasing cathepsin V transcription[1].
Cathepsin V preferentially cleaves glycine-rich motifs in elastin, producing EDPs enriched in the VGV sequence that have been shown to potentiate ERC signaling 2.8- to 3.2-fold[2].
ERC engagement activates FAK/Src/Ras-Raf-MEK-ERK pathways, but sustained ERK signaling also promotes NLRP3 inflammasome assembly via ROS-mediated TXNIP dissociation[3].
NLRP3 activation leads to caspase-1-dependent IL-1beta maturation; IL-1beta signaling through IL-1R activates NF-kappaB, which can inhibit prolyl hydroxylases and stabilize HIF-1alpha even under normoxia[4].
Thus, hypoxia-induced HIF-1alpha → cathepsin V → EDPs → ERC → NLRP3/IL-1beta → HIF-1alpha forms a self-reinforcing circuit that explains the observed vicious cycle of reduced tropoelastin synthesis and accelerated degradation[5].

Testable Predictions

In primary human aortic smooth muscle cells cultured at 3% O2, HIF-1alpha knockdown (siRNA) will reduce cathepsin V mRNA and protein levels by >50% and decrease EDP generation measured by ELISA[6].
Pharmacologic inhibition of HIF-1alpha (e.g., with YC-1) will blunt cathepsin V up-regulation and attenuate ERK phosphorylation and calcium deposition in vitro.
Overexpression of cathepsin V in normoxic cells will mimic hypoxic EDP production and enhance ERC-dependent ERK signaling, an effect abolished by cathepsin V-specific inhibitor.
NLRP3 deficiency (CRISPR KO or MCC950 treatment) will block IL-1beta release and downstream ERK activation despite high EDP levels, uncoupling ERC signaling from calcification.
In vivo, VSMC-specific Hif1a-null mice exposed to chronic hypoxia (10% O2) will exhibit lower arterial elastin fragmentation, reduced EDPs, and diminished calcium burden compared with wild-type littermates, despite similar blood pressure.

Potential Experiments

In vitro: Treat HASMCs with hypoxia mimic CoCl2; assess HIF-1alpha, cathepsin V, elastin fragments (Western blot for desmosine), EDPs (ELISA), phospho-ERK, and Alizarin Red staining. Use siRNA, CRISPR, and small-molecule inhibitors.
In vivo: Generate SM22alpha-Cre;Hif1a^fl/fl mice; subject to intermittent hypoxia; perform micro-CT for calcification, immunostaining for cathepsin V, EDPs (using VGV-specific antibody), and NLRP3 inflammasome components.
Biomarker: Correlate plasma HIF-1alpha-dependent cathepsin V levels with circulating EDPs and pulse-wave velocity in a cohort of patients with chronic kidney disease.

Implications

If validated, this hypothesis repositions hypoxia not merely as a suppressor of elastin synthesis but as an active driver of proteolytic elastin catabolism that couples to innate immunity via the NLRP3 inflammasome. Therapeutically, targeting the HIF-1alpha-cathepsin V axis or blocking NLRP3 could break the feed-forward loop, offering a dual approach to prevent elastin loss and calcification.

References [1] https://pmc.ncbi.nlm.nih.gov/articles/PMC6609650/ [2] https://academic.oup.com/ajrcmb/article/5/5/464/8511718 [3] https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.815356/full [4] https://news.ki.se/osteomodulin-is-a-novel-biomarker-of-vascular-calcification [5] https://www.liebertpub.com/doi/10.1089/ten.tec.2016.0173 [6] https://www.semanticscholar.org/paper/db65eda0f05158d8518393069af63ea1df1f32e8